{
    "clinical_study": {
        "@rank": "33614", 
        "arm_group": [
            {
                "arm_group_label": "Probiotics", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Control placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To demonstrate benefit of a probiotic product in adults with irritable bowel syndrome."
        }, 
        "brief_title": "The Effect of Probiotics on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Irritable Bowel Syndrome", 
        "condition_browse": {
            "mesh_term": "Irritable Bowel Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing and able to provide informed consent\n\n          -  Age \u226518 and \u226470 years at Visit 1\n\n          -  IBS according to the Rome III criteria\n\n          -  A score on abdominal pain NRS \u22653 and \u22646 at least two days a week measured the weeks\n             before Visit 2 (baseline)\n\n          -  IBS-SSS  \u226575 and \u2264300 at Visit 2 (baseline)\n\n          -  Ability and willingness to understand and comply with the study procedures\n\n        Exclusion Criteria:\n\n          -  Known intolerance or allergy to milk products (protein or lactose) or gluten\n\n          -  History of alcohol or substance abuse six months prior to screening\n\n          -  Known Hepatitis B or C or Human Immunodeficiency Virus (HIV) 1 or 2\n\n          -  Female patients: currently pregnant or breast-feeding or intending to become pregnant\n             during the study\n\n          -  Abnormal results of the screening laboratory tests  clinically relevant for study\n             participation, as judged by the Investigator\n\n          -  Other gastrointestinal disease(s) that explains the patient's symptoms, as judged by\n             the Investigator\n\n          -  Other severe disease(s) such as malignancy, severe coronary disease, kidney disease\n             or neurological disease, as judged by the Investigator\n\n          -  Symptoms indicating other severe disease(s) such as gastrointestinal bleeding, loss\n             of weight or fever, as judged by the Investigator\n\n          -  Severe psychiatric disease as judged by the Investigator\n\n          -  Lack of suitability for participation in the study for any reason as judged by the\n             Investigator\n\n          -  Use of other probiotic products from Visit 1 and throughout the study.\n\n          -  Consumption of antibiotic drugs 1 month prior to screening and throughout the study.\n\n          -  Consumption of drugs on a regular basis which could interfere with symptom evaluation\n             as judged by the Investigator."
            }, 
            "gender": "Both", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "April 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02108119", 
            "org_study_id": "PRO008"
        }, 
        "intervention": [
            {
                "arm_group_label": "Probiotics", 
                "intervention_name": "Probiotics", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Control placebo", 
                "intervention_name": "Control placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beek", 
                    "country": "Netherlands", 
                    "zip": "6191"
                }, 
                "name": "PreCare Trial & Recruitment"
            }, 
            "investigator": {
                "last_name": "Vivienne van de Walle, Med dr", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "vivienne.vandewalle@ptr.nu", 
            "last_name": "Vivienne van de Walle, Med dr", 
            "phone": "+31 46 475 8687"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "The Netherlands: Ethical committee"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "0-10 numeric rating scale (NRS)", 
            "measure": "Abdominal pain", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02108119"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Probi AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Probi AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}